INTRODUCTION: Prevalence estimates of attention deficit hyperactivity disorder (ADHD) vary according to the diagnostic criteria used and the population sampled. DSM-IV prevalence estimates among school children in the US are 3% to 5%, but other estimates vary from 1.7% to 16.0%. No objective test exists to confirm the diagnosis of ADHD, which remains a clinical diagnosis. Other conditions frequently co-exist with ADHD. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of pharmacological treatments for ADHD in children and adolescents? What are the effects of psychological treatments for ADHD in children and adolescents? What are the effects of combination treatments for ADHD in children and adolescents? We searched: Medline, Embase, The Cochrane Library, and other important databases up to August 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 70 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: atomoxetine, bupropion, clonidine, dexamfetamine sulphate, homeopathy, methylphenidate, modafinil, omega-3 polyunsaturated fatty acids, and psychological/behavioural treatment (either alone or in combination with a drug treatment).
INTRODUCTION: Prevalence estimates of attention deficit hyperactivity disorder (ADHD) vary according to the diagnostic criteria used and the population sampled. DSM-IV prevalence estimates among school children in the US are 3% to 5%, but other estimates vary from 1.7% to 16.0%. No objective test exists to confirm the diagnosis of ADHD, which remains a clinical diagnosis. Other conditions frequently co-exist with ADHD. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of pharmacological treatments for ADHD in children and adolescents? What are the effects of psychological treatments for ADHD in children and adolescents? What are the effects of combination treatments for ADHD in children and adolescents? We searched: Medline, Embase, The Cochrane Library, and other important databases up to August 2009 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 70 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: atomoxetine, bupropion, clonidine, dexamfetamine sulphate, homeopathy, methylphenidate, modafinil, omega-3 polyunsaturated fatty acids, and psychological/behavioural treatment (either alone or in combination with a drug treatment).
Authors: Margaret Weiss; Rosemary Tannock; Christopher Kratochvil; David Dunn; Jesus Velez-Borras; Christine Thomason; Roy Tamura; Douglas Kelsey; Linda Stevens; Albert J Allen Journal: J Am Acad Child Adolesc Psychiatry Date: 2005-07 Impact factor: 8.829
Authors: S King; S Griffin; Z Hodges; H Weatherly; C Asseburg; G Richardson; S Golder; E Taylor; M Drummond; R Riemsma Journal: Health Technol Assess Date: 2006-07 Impact factor: 4.014
Authors: Thomas J Spencer; Jeffrey H Newcorn; Christopher J Kratochvil; Dustin Ruff; David Michelson; Joseph Biederman Journal: Pediatrics Date: 2005-07 Impact factor: 7.124
Authors: Stephen V Faraone; Roy H Perlis; Alysa E Doyle; Jordan W Smoller; Jennifer J Goralnick; Meredith A Holmgren; Pamela Sklar Journal: Biol Psychiatry Date: 2005-01-21 Impact factor: 13.382
Authors: William E Pelham; Michael J Manos; Cora E Ezzell; Katy E Tresco; Elizabeth M Gnagy; Martin T Hoffman; Adia N Onyango; Gregory A Fabiano; Andy Lopez-Williams; Brian T Wymbs; Donald Caserta; Andrea M Chronis; Lisa Burrows-Maclean; Gene Morse Journal: J Am Acad Child Adolesc Psychiatry Date: 2005-06 Impact factor: 8.829
Authors: Raul Silva; Rafael Muniz; Linda K Pestreich; Matthew Brams; Ann Childress; Frank A Lopez Journal: J Child Adolesc Psychopharmacol Date: 2005-08 Impact factor: 2.576
Authors: Joseph Biederman; James M Swanson; Sharon B Wigal; Samuel W Boellner; Craig Q Earl; Frank A Lopez Journal: J Clin Psychiatry Date: 2006-05 Impact factor: 4.384
Authors: Yufeng Wang; Yi Zheng; Yasong Du; Dong H Song; Yee-Jin Shin; Soo C Cho; Bung N Kim; Dong H Ahn; Maria E Marquez-Caraveo; Haitao Gao; David W Williams; Louise R Levine Journal: Aust N Z J Psychiatry Date: 2007-03 Impact factor: 5.744
Authors: Ferrán Catalá-López; Brian Hutton; Amparo Núñez-Beltrán; Alain D Mayhew; Matthew J Page; Manuel Ridao; Aurelio Tobías; Miguel A Catalá; Rafael Tabarés-Seisdedos; David Moher Journal: Syst Rev Date: 2015-02-27
Authors: Ferrán Catalá-López; Brian Hutton; Amparo Núñez-Beltrán; Matthew J Page; Manuel Ridao; Diego Macías Saint-Gerons; Miguel A Catalá; Rafael Tabarés-Seisdedos; David Moher Journal: PLoS One Date: 2017-07-12 Impact factor: 3.240